<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Loteprednol: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Loteprednol: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Loteprednol: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10116" href="/d/html/10116.html" rel="external">see "Loteprednol: Drug information"</a> and <a class="drug drug_patient" data-topicid="11179" href="/d/html/11179.html" rel="external">see "Loteprednol: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F190305"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Alrex;</li>
<li>Eysuvis;</li>
<li>Inveltys;</li>
<li>Lotemax;</li>
<li>Lotemax SM</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867405"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Alrex;</li>
<li>Lotemax</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1022677"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Corticosteroid, Ophthalmic</span></li></ul></div>
<div class="block don drugH1Div" id="F53462498"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1f676344-860a-42cf-a55e-cb1d3af78e91">Postoperative inflammation and pain</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Postoperative inflammation and pain:</b> Term Neonates: Ophthalmic: 0.5% gel (Lotemax): Instill 1 to 2 drops into the conjunctival sac of the affected eye(s) 4 times daily beginning postoperative day 1 and continuing throughout the first 2 weeks of the postoperative period; pediatric trials included patients from birth to 11 years (mean age: 3 years) undergoing cataract surgery.</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F53154207"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1f676344-860a-42cf-a55e-cb1d3af78e91">Postoperative inflammation and pain</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Postoperative inflammation and pain:</b> Infants, Children, and Adolescents: Ophthalmic: 0.5% gel (Lotemax): Instill 1 to 2 drops into the conjunctival sac of the affected eye(s) 4 times daily beginning postoperative day 1 and continuing throughout the first 2 weeks of the postoperative period; trials in young pediatric patients (mean age: 3 years) were conducted following cataract surgery.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F53154208"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely due to low systemic absorption.</p></div>
<div class="block dohp drugH1Div" id="F53154209"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely due to low systemic absorption.</p></div>
<div class="block doa drugH1Div" id="F190307"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10116" href="/d/html/10116.html" rel="external">see "Loteprednol: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4993b190-760b-4de4-b033-07a2e036dc6e">Dry eye disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dry eye disease: Ophthalmic:</b> 0.25% suspension: Instill 1 to 2 drops into each eye 4 times daily for up to 2 weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="539a5941-a3c3-4281-8579-6c7c57afa01f">Ophthalmic inflammatory conditions</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ophthalmic inflammatory conditions:</b>
<b>Ophthalmic:</b> 0.5% suspension: Instill 1 to 2 drops into the conjunctival sac of the affected eye(s) 4 times daily. During the initial treatment within the first week, the dosing may be increased up to 1 drop every hour. Do not discontinue therapy prematurely; withdraw therapy with gradual tapering of dose in chronic conditions. If signs and symptoms fail to improve after 2 days, re-evaluate the patient.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ec01de31-0186-441d-bcea-b30fe61de6b7">Postoperative ophthalmic inflammation/pain</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Postoperative ophthalmic inflammation/pain:</b>
<b>Ophthalmic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">0.38% gel: Apply 1 drop into the conjunctival sac of the affected eye(s) 3 times daily beginning 24 hours after surgery and continuing throughout the first 2 weeks of the postoperative period.</p>
<p style="text-indent:-2em;margin-left:4em;">0.5% ointment: Apply ~<sup>1</sup>/<sub>2</sub> inch ribbon into the conjunctival sac of the affected eye(s) 4 times daily beginning 24 hours after surgery and continuing throughout the first 2 weeks of the postoperative period.</p>
<p style="text-indent:-2em;margin-left:4em;">0.5% gel, 0.5% suspension: Instill 1 to 2 drops into the conjunctival sac of the affected eye(s) 4 times daily beginning 24 hours after surgery and continuing throughout the first 2 weeks of the postoperative period.</p>
<p style="text-indent:-2em;margin-left:4em;">1% suspension: Instill 1 to 2 drops into the affected eye(s) twice daily beginning the day after surgery and continuing throughout the first 2 weeks of the postoperative period.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3d370684-2ec0-4b63-b0a3-f27e0ece0341">Seasonal allergic conjunctivitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seasonal allergic conjunctivitis:</b>
<b>Ophthalmic:</b> 0.2% suspension: Instill 1 drop into affected eye(s) 4 times daily.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50992045"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.</p></div>
<div class="block doha drugH1Div" id="F50989291"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.</p></div>
<div class="block adr drugH1Div" id="F190290"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Chemosis (5% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application site burning (5% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (2% to &lt;15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Anterior chamber inflammation (2% to 25%), blurred vision (5% to 15%), epiphora (5% to 15%), eye discharge (5% to 15%), eye pruritus (5% to 15%), foreign body sensation of eye (2% to 15%), injected sclera (5% to 15%), photophobia (5% to 15%), visual disturbance (5% to 15%), xerophthalmia (5% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pharyngitis (&lt;15%), rhinitis (&lt;15%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema of eyelid (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application site pain (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctival hyperemia (4% to 5%), conjunctivitis (&lt;5%), corneal changes (&lt;5%), corneal edema (4% to 5%), eye discomfort (&lt;5%), eye irritation (&lt;5%), eye pain (1% to 5%), increased intraocular pressure (2%), keratoconjunctivitis (&lt;5%), secondary cataract (1%), uveitis (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Papilla (&lt;5%)</p></div>
<div class="block coi drugH1Div" id="F190300"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to loteprednol, other corticosteroids, and any component of the formulation; viral disease of the cornea and conjunctiva (including epithelial herpes simplex keratitis, vaccinia, varicella); mycobacterial infection of the eye; fungal disease of ocular structures.</p></div>
<div class="block war drugH1Div" id="F190287"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cataracts: Use of corticosteroids may result in posterior subcapsular cataract formation. Use following cataract surgery may delay healing and increase the incidence of bleb formation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Corneal thinning: Various ophthalmic disorders, as well as prolonged use of corticosteroids, may result in corneal and scleral thinning. Continued use in a patient with thinning may result in perforation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Glaucoma: Prolonged use of corticosteroids may result in elevated intraocular pressure (IOP) and/or glaucoma; damage to the optic nerve; and defects in visual acuity and fields of vision. Use with caution in patients with glaucoma; monitor IOP in any patient receiving treatment for ≥10 days.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunosuppression: Prolonged use of corticosteroids (including ophthalmic preparations) may increase the incidence of secondary ocular infections (including fungal infections). Acute purulent ocular infections may be masked or exacerbated with use. Fungal infection should be suspected in any patient with persistent corneal ulceration who has received corticosteroids.</p>
<p style="text-indent:-2em;margin-left:4em;">• Systemic absorption: Studies have demonstrated topical ophthalmic corticosteroids are absorbed systemically and may cause endogenous corticosteroid production reduction. Caution is advised with prolonged use of topical ophthalmic corticosteroids in terms of systemic immunosuppression and additional systemic hazard of corticosteroid exposure (Burch 1968).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns: </b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Herpes simplex: Corticosteroids should not be used to treat ocular herpes simplex; may exacerbate the severity of the infection. Use extreme caution in patients with history of herpes simplex.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Contact lens wearers: Some preparations may contain benzalkonium chloride, which may be absorbed by contact lenses. Contact lenses should not be worn when using loteprednol 0.38% gel or 0.5% ophthalmic gel, ointment, or suspension. However, contact lenses may be reinserted 15 minutes following administration of loteprednol 0.25% and 1% ophthalmic suspension or ≥10 minutes following administration of loteprednol 0.2% ophthalmic suspension.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Avoid use of ointment in children following amblyopia treatment since ointment consistency may hinder ability to see out of treated eye.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP ["Inactive" 1997]; Zar 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acute anterior uveitis: More potent steroids may be required for this indication.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: For ophthalmic use only; patients should be re-evaluated if symptoms fail to improve after 2 days. Initial prescription and renewal of medication after 14 days should be made by healthcare provider only after examination with the aid of magnification such as slit lamp biomicroscopy or fluorescein staining (if appropriate) and evaluation of intraocular pressure (0.25% suspension). Avoid contamination; do not touch tip of applicator or let tip of applicator touch eye.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F53154205"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Increased intraocular pressure (IOP) may occur especially with prolonged use of ophthalmic corticosteroids; in children on ophthalmic dexamethasone, increased IOP has been shown to be dose dependent and produce a greater IOP in children &lt;6 years than older children (Lam 2005).</p>
<p style="text-indent:0em;margin-top:2em;">Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F190295"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Gel, Ophthalmic, as etabonate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lotemax: 0.5% (5 g) [contains benzalkonium chloride, edetate (edta) disodium dihydrate, propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lotemax SM: 0.38% (5 g) [contains benzalkonium chloride, edetate (edta) disodium dihydrate, propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5% (5 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Ointment, Ophthalmic, as etabonate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lotemax: 0.5% (3.5 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Ophthalmic: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Eysuvis: 0.25% (8.3 mL) [contains benzalkonium chloride, edetate (edta) disodium dihydrate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Inveltys: 1% (2.8 mL) [contains benzalkonium chloride, edetate (edta) disodium dihydrate]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Ophthalmic, as etabonate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Alrex: 0.2% (5 mL, 10 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lotemax: 0.5% (5 mL, 10 mL, 15 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5% (5 mL, 10 mL, 15 mL)</p></div>
<div class="block geq drugH1Div" id="F190283"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F190301"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Lotemax Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5% (per gram): $61.26</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Lotemax SM Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.38% (per gram): $61.26</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Loteprednol Etabonate Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5% (per gram): $46.24</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Ointment</b> (Lotemax Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5% (per gram): $123.14</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Alrex Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.2% (per mL): $71.77</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Eysuvis Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25% (per mL): $73.45</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Inveltys Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1% (per mL): $129.29</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Lotemax Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5% (per mL): $76.34</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Loteprednol Etabonate Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5% (per mL): $45.07 - $51.29</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867406"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Gel, Ophthalmic, as etabonate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lotemax: 0.5% (5 g) [contains benzalkonium chloride, edetate (edta) disodium dihydrate, propylene glycol]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Ointment, Ophthalmic, as etabonate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lotemax: 0.5% (3.5 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Ophthalmic, as etabonate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Alrex: 0.2% (5 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lotemax: 0.5% (5 mL, 10 mL)</p></div>
<div class="block admp drugH1Div" id="F53154210"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Ophthalmic: For topical ophthalmic use. Avoid contamination; do not touch dropper or tube tip to eyelids or other surfaces. Remove contacts prior to administration; contact lenses should not be worn when using loteprednol gel.</p>
<p style="text-indent:-2em;margin-left:4em;">Gel: While bottle is closed, invert and shake once to fill tip prior to instilling drops.</p></div>
<div class="block adm drugH1Div" id="F190297"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Ophthalmic:</b> For topical ophthalmic use only; wash hands before use. To avoid contamination, do not touch dropper or tube tip to eyelids or other surfaces. Remove contacts prior to administration. Contact lenses should not be worn when using ophthalmic gel, ointment, or suspension. However, contact lenses may be reinserted 15 minutes following administration of loteprednol 0.25% and 1% ophthalmic suspension or ≥10 minutes following administration of loteprednol 0.2% ophthalmic suspension. When used for the treatment of seasonal allergic conjunctivitis, do not wear contacts if eyes are red.</p>
<p style="text-indent:-2em;margin-left:4em;">Gel: While bottle is closed, invert and shake once to fill tip prior to instilling drops.</p>
<p style="text-indent:-2em;margin-left:4em;">Suspension: Shake well before using. The manufacturer's labeling for the 0.25% and 1% suspension formulation recommends separating administration of other ophthalmic agents by at least 5 minutes.</p></div>
<div class="block sts drugH1Div" id="F13228878"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 15°C to 25°C (59°F to 77°F); do not freeze.</p></div>
<div class="block usep drugH1Div" id="F53567602"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Ophthalmic:</p>
<p style="text-indent:-2em;margin-left:4em;">Gel:</p>
<p style="text-indent:-2em;margin-left:6em;">0.38% gel (Lotemax SM): Treatment of postoperative inflammation and pain following ocular surgery (FDA approved in adults)</p>
<p style="text-indent:-2em;margin-left:6em;">0.5% gel (Lotemax): Treatment of postoperative inflammation and pain following ocular surgery (FDA approved in all ages)</p>
<p style="text-indent:-2em;margin-left:4em;">Ointment (Lotemax 0.5%): Treatment of postoperative inflammation and pain following ocular surgery (FDA approved in adults)</p>
<p style="text-indent:-2em;margin-left:4em;">Suspension:</p>
<p style="text-indent:-2em;margin-left:6em;">0.2% suspension (Alrex): Temporary relief of signs and symptoms of seasonal allergic conjunctivitis (FDA approved in adults)</p>
<p style="text-indent:-2em;margin-left:6em;">0.5% suspension (Lotemax): Treatment of steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe (eg, allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitis, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation); treatment of postoperative inflammation following ocular surgery (All indications: FDA approved in adults)</p>
<p style="text-indent:-2em;margin-left:6em;">1% suspension (Inveltys): Treatment of postoperative inflammation and pain following ocular surgery (FDA approved in adults)</p></div>
<div class="block cyt drugH1Div" id="F13299617"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6221369"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F13228758"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">The amount of loteprednol absorbed systemically following ophthalmic administration is not known but expected to be &lt;1 ng/mL.</p>
<p style="text-indent:0em;margin-top:2em;">If ophthalmic agents are needed during pregnancy, the minimum effective dose should be used in combination with punctal occlusion to decrease potential exposure to the fetus (Samples 1988).</p></div>
<div class="block mopp drugH1Div" id="F53567597"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Intraocular pressure (especially with use &gt;10 days); signs or symptoms of ocular infection</p></div>
<div class="block pha drugH1Div" id="F190286"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Corticosteroids inhibit the inflammatory response including edema, capillary dilation, leukocyte migration, and scar formation. Loteprednol is highly lipid soluble and penetrates cells readily to induce the production of lipocortins. These proteins modulate the activity of prostaglandins and leukotrienes.</p></div>
<div class="block phk drugH1Div" id="F190299"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Seasonal allergic conjunctivitis: Reduction of symptoms seen within 2 hours of instillation.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Minimal; chronic ophthalmic administration resulted in plasma levels of loteprednol and its metabolite below the level of quantitation (1 ng/mL).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Penetrates most readily into the cornea, followed by the iris/ciliary body and aqueous humor.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Metabolized to inactive carboxylic acid metabolites by corneal esterases primarily in the cornea. Once the glucocorticoid receptor is activated, loteprednol undergoes rapid metabolism and minimizing adverse effects (Sheppard 2016).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F190302"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Lotemax</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Alrex | Lopred | Lotemax | Lotesoft | Lotevis | Talof</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Lotemax</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Lotemax</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Lacrison | Loteflam | Lotenol | Lotepred | Lotepred DS | Lotepro | Lotepro ds | Loterex | Lotrel</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Alrex | Loteprol</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Disalot | Oftol | Talof</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Lotemax</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Disalot | Lotepred | Loteprednol etabonato | Lotesoft | Oftaprednol | Oftaprednol max | Talof | Trakirol | Visionfree</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Lotemax</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Lotesoft | Oftol | Talof</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Lotesoft | Oftol forte</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Lotemax</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Alrex</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Alrex | Lotemax</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Lotemax</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Ednol | Erpetol | Esenlote | Etapred | L pred | Lorinol | Lot ls | Lotechek | Lotefast | Loteflam | Lotel | Lotemed | Lotepred | Loteris | Lotesol | Lotesurge | Lotezop | Pidone | Prednol | Prednol ls</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Lotemax</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Lotemax</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Lotemax | Lotepro</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Lotemax</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Lotemax</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Lotemax | Lotepred</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Lotemax</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Loterex | Lotesoft</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Lotemax</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Lotemax</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Lotesoft</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Lotemax</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Alzapred forte | Dinflox | Ednol plus | Lopred | Loteflam | Lotemax | Lotemic | Lotenol forte | Lotepred fort | Lotinol | Loton | Loty forte</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Alrex | Eysuvis | Inveltys | Lotemax</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Lotaris | Lotesoft | Ocugard | Oftol | Oftol forte</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Lotemax</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Lotemax</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Lotemax</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Lotemax</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Alrex | Lotemax</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Lotemax</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Dolte | Loteforte</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Alrex | Lotemax</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Lotemax | Lotesoft</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Alrex | Lotemax</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Alrex.1">
<a name="Alrex.1"></a>Alrex (loteprednol) [prescribing information]. Tampa, FL: Bausch &amp; Lomb Inc; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loteprednol-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5635343">
<a name="5635343"></a>Burch PG, Migeon CJ. Systemic absorption of topical steroids. <i>Arch Ophthalmol</i>. 1968;79(2):174-176. doi: 10.1001/archopht.1968.03850040176013.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loteprednol-pediatric-drug-information/abstract-text/5635343/pubmed" id="5635343" target="_blank">5635343</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22536546">
<a name="22536546"></a>Comstock TL, Decory HH. Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate.<i> Int J Inflam</i>. 2012;2012:789623. doi: 10.1155/2012/789623.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loteprednol-pediatric-drug-information/abstract-text/22536546/pubmed" id="22536546" target="_blank">22536546</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1959381">
<a name="1959381"></a>Druzgala P, Wu WM, Bodor N. Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes. <i>Curr Eye Res</i>. 1991;10(10):933-937. doi: 10.3109/02713689109020329.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loteprednol-pediatric-drug-information/abstract-text/1959381/pubmed" id="1959381" target="_blank">1959381</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eysuvis.1">
<a name="Eysuvis.1"></a>Eysuvis (loteprednol) [prescribing information]. Arlington, MA; Kala Pharmaceuticals Inc: March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9572541">
<a name="9572541"></a>Howes J, Novack GD. Failure to detect systemic levels, and effects of loteprednol etabonate and its metabolite, PJ-91, following chronic ocular administration.<i> J Ocul Pharmacol Ther</i>. 1998;14(2):153-158. doi: 10.1089/jop.1998.14.153.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loteprednol-pediatric-drug-information/abstract-text/9572541/pubmed" id="9572541" target="_blank">9572541</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Inveltys.1">
<a name="Inveltys.1"></a>Inveltys (loteprednol) [prescribing information]. Arlington, MA: Kala Pharmaceuticals Inc; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15932528">
<a name="15932528"></a>Lam DS, Fan DS, Ng JS, et al. Ocular hypertensive and anti-inflammatory responses to different dosages of topical dexamethasone in children: a randomized trial. <i>Clin Experiment Ophthalmol</i>. 2005;33(3):252-258.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loteprednol-pediatric-drug-information/abstract-text/15932528/pubmed" id="15932528" target="_blank">15932528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lotemax.1">
<a name="Lotemax.1"></a>Lotemax gel (loteprednol) [prescribing information]. Bridgewater, NJ: Bausch &amp; Lomb; April 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lotemax.2">
<a name="Lotemax.2"></a>Lotemax ointment (loteprednol) [prescribing information]. Tampa, FL: Bausch &amp; Lomb Inc; May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lotemax.3">
<a name="Lotemax.3"></a>Lotemax gel (loteprednol) [prescribing information]. Tampa, FL: Bausch &amp; Lomb Inc; August 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lotemax.4">
<a name="Lotemax.4"></a>Lotemax ointment (loteprednol) [prescribing information]. Tampa, FL: Bausch &amp; Lomb Inc; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lotemax.5">
<a name="Lotemax.5"></a>Lotemax SM ophthalmic gel (loteprednol) [prescribing information]. Tampa, FL: Bausch &amp; Lomb Inc; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lotemax.6">
<a name="Lotemax.6"></a>Lotemax suspension (loteprednol) [prescribing information]. Tampa, FL: Bausch &amp; Lomb Inc; May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28924342">
<a name="28924342"></a>Phulke S, Kaushik S, Kaur S, Pandav SS. Steroid-induced glaucoma: an avoidable irreversible blindness.<i> J Curr Glaucoma Pract</i>. 2017;11(2):67-72. doi: 10.5005/jp-journals-l0028-1226.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loteprednol-pediatric-drug-information/abstract-text/28924342/pubmed" id="28924342" target="_blank">28924342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16236742">
<a name="16236742"></a>Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. <i>N Engl J Med</i>. 2005;353(16):1711-1723. doi: 10.1056/NEJMra050541.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loteprednol-pediatric-drug-information/abstract-text/16236742/pubmed" id="16236742" target="_blank">16236742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2903673">
<a name="2903673"></a>Samples JR, Meyer SM. Use of ophthalmic medications in pregnant and nursing women. <i>Am J Ophthalmol</i>. 1988;106(5):616-623.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loteprednol-pediatric-drug-information/abstract-text/2903673/pubmed" id="2903673" target="_blank">2903673</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15684812">
<a name="15684812"></a>Samudre SS, Lattanzio FA Jr, Williams PB, Sheppard JD Jr. Comparison of topical steroids for acute anterior uveitis. <i>J Ocul Pharmacol Ther</i>. 2004;20(6):533-547. doi: 10.1089/jop.2004.20.533.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loteprednol-pediatric-drug-information/abstract-text/15684812/pubmed" id="15684812" target="_blank">15684812</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22344184">
<a name="22344184"></a>Sandhu SS, Smith JM, Doherty M, James A, Figueiredo FC. Do topical ophthalmic corticosteroids suppress the hypothalmic-pituitary-adrenal axis in post-penetrating keratoplasty patients? <i>Eye (Lond)</i>. 2012;26(5):699-702. doi: 10.1038/eye.2012.12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loteprednol-pediatric-drug-information/abstract-text/22344184/pubmed" id="22344184" target="_blank">22344184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loteprednol-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26984315">
<a name="26984315"></a>Sheppard JD, Comstock TL, Cavet ME. Impact of the topical ophthalmic corticosteroid loteprednol etabonate on intraocular pressure. <i>Adv Ther</i>. 2016;33(4):532-552. doi: 10.1007/s12325-016-0315-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loteprednol-pediatric-drug-information/abstract-text/26984315/pubmed" id="26984315" target="_blank">26984315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loteprednol-pediatric-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 121401 Version 91.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
